Innoviva, Inc. (INVA) Stock Price & Analysis
Innoviva, Inc. (INVA) closed at USD 21.31 on Thursday, October 29, 2026, up 0.90% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 21.12; the Oct 29, 2026 session ranged USD 21.12–21.52 on volume of 626,925 shares. Market capitalization is $1.54B, with a 52-week range of USD 17.53–25.15 (NMS). Source: Nexqual, retrieved October 29, 2026 at 23:44 UTC.
Also available as compact Markdown for AI agents: nexqual.com/INVA.md
Key facts (INVA)
- Valuation: P/E 4.3x (avg 23.0x at the last 3 fiscal year-ends), net cash $312M.
- Analysts: Buy (mean 2.40 on a 1–5 scale) (5 analysts), mean target USD 35 (range 18–46).
- Total return with dividends: 1Y +18.7% vs S&P 500 +14.4%; 5Y +22.1% vs S&P 500 +79.1%.
- Next earnings: 2026-11-04 (date not yet confirmed by the company), EPS estimate USD 0.34, revenue estimate $115M. All companies reporting that day: https://nexqual.com/earnings/2026-11-04
- Dividend: INVA paid no cash dividend in the last five years.
- Short interest: 13.66% of float (as of 2026-10-15), 7.4 days to cover.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (INVA)
P/E 4.3x · P/S 3.5x · EV/Sales 2.8x · P/FCF 8.1x · P/B 1.2x · FCF yield 12.42% · Earnings yield 23.41% · Buyback yield (TTM) 3.66% · Net cash $312M · EV $1.21B
P/E at fiscal year-ends: Dec 2025 6.2x, Dec 2024 55.0x, Dec 2023 7.8x.
Analysts (INVA)
Consensus Buy (mean 2.40 on a 1–5 scale), 5 analysts; mean target USD 35 (low 18, high 46).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | Cantor Fitzgerald | Target lowered | Overweight | $36 → $34 |
Total return (dividends reinvested) (INVA)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +18.7% | +22.1% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | +18.8% | +4.1% |
| Volatility (annualized) | 26.8% | 26.9% |
| Max drawdown | -16.5% (Feb 2026→Sep 2026) | -46.0% (Feb 2022→Mar 2023) |
Dividends (INVA)
INVA paid no cash dividend in the last five years.
Short interest (INVA)
7,265,728 shares sold short, 13.66% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 7,144,265 shares (+1.7%). Days to cover: 7.4 (short shares ÷ average daily volume).
INVA earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.56 | $0.50 | Beat +12.0% | — |
| — | Quarter ended Mar 31, 2026 | $0.47 | $0.43 | Beat +9.3% | — |
| — | Quarter ended Dec 31, 2025 | $0.47 | $0.43 | Beat +9.3% | — |
| — | Quarter ended Sep 30, 2025 | $0.38 | $0.39 | Miss −2.6% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
Companies that name INVA in their SEC reports
| Relationship to INVA | Company | Filing | Sentence |
|---|---|---|---|
| partner | Armata Pharmaceuticals, Inc. (ARMP) | 10-K Mar 25, 2026 | “Concurrently with the execution of the 2024 Credit Agreement, we amended certain provisions of the Convertible Loan and Convertible Credit Agreement and the secured term loan facility in the aggregate amount of $25.0 million (the "2023 Loan") and 2023 Credit Agreement with Innoviva Sub, to, among other things, conform certain terms relating to permitted indebtedness and permitted liens.” |
| customer | Zai Lab Ltd (ZLAB) | 10-K Feb 26, 2026 | “For example, we source VYVGART and VYVGART Hytrulo from argenx, OPTUNE from NovoCure, QINLOCK from Deciphera, XACDURO from Innoviva, AUGTYRO from BMS, and TIVDAK from Pfizer.” |
INVA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.34 | $0.38 | -10.5% | $115.3M | 5 |
| Next quarter (ends Dec 2026) | $0.52 | $0.59 | -11.9% | $118.4M | 5 |
| Current fiscal year (ends Dec 2026) | $2.23 | $3.34 | -33.1% | $451.3M | 5 |
| Next fiscal year (ends Dec 2027) | $2.26 | $2.29 | -1.1% | $490.0M | 5 |
Key Statistics (as of October 29, 2026 at 23:44 UTC)
| Price | USD 21.31 |
|---|---|
| Change | ▲ 0.90% (up) |
| Previous Close | USD 21.12 |
| Open | USD 21.41 |
| Day Range | USD 21.12 – 21.52 |
| 52-Week Range | USD 17.53 – 25.15 |
| Volume | 626,925 shares |
| Market Cap | $1.54B |
| Exchange | NMS |
Technical Analysis (INVA)
Nexqual's technical model rates INVA "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 29, 2026 at 23:44 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 55.17 (neutral) |
| vs SMA50 | Above (USD 20.99) |
| MACD | 0.03 (positive) |
Analyst Ratings (INVA)
Wall Street analysts rate INVA "Buy" based on 5 analysts, with a mean price target of USD 35 (range USD 18–46), per Nexqual as of October 29, 2026 at 23:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 35 |
| High Target | USD 46 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 4 / 0 / 1 |
Earnings (INVA)
| Next Earnings Date | 2026-11-04 |
|---|---|
| Revenue Estimate | $115.31M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.56 vs est 0.5 ▲ beat |
| 2026-03-31 | USD 0.47 vs est 0.43 ▲ beat |
| 2025-12-31 | USD 0.47 vs est 0.43 ▲ beat |
| 2025-09-30 | USD 0.38 vs est 0.39 ▼ miss |
Source: Nexqual, October 29, 2026 at 23:44 UTC.
Financials & Fundamentals (INVA)
| Total Revenue | $440.00M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +19.30% |
| Gross Margin | +72.67% |
| Operating Margin | +43.28% |
| Profit Margin | +81.19% |
| ROE | +36.68% |
| Debt / Equity | 0.27 |
| Current Ratio | 16.01 |
| Total Cash | $579.06M |
| Total Debt | $331.24M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | $195.80M (47.6% of revenue) |
Source: Nexqual, October 29, 2026 at 23:44 UTC.
Financial Health Score (INVA)
Nexqual rates Innoviva, Inc.'s overall financial health "Strong" across five dimensions, as of October 29, 2026 at 23:44 UTC.
| Growth | Solid — Revenue +15% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 73%, operating 43% (last 12 months) |
| Balance Sheet | Strong — $579M cash vs $331M debt, net cash position |
| Cash Flow | Strong — FCF $196M (FY ended Dec 2025, 10-K), 48% margin |
| Efficiency | Strong — ROE 37%, ROA 6.9% |
Ownership (INVA)
| Insider Ownership | +1.01% |
|---|---|
| Institutional Ownership | +108.93% |
| Shares Outstanding | 72.25M |
| Float | 67.65M |
| Short % of Float | +13.66% |
Source: Nexqual, October 29, 2026 at 23:44 UTC.
Leadership (INVA)
Innoviva, Inc. is led by Pavel Raifeld C.F.A., CEO & Director, per Nexqual as of October 29, 2026 at 23:44 UTC.
| CEO & Director | Pavel Raifeld C.F.A. |
|---|---|
| Chief Financial Officer | Stephen Basso |
Major Backers & Investors (INVA)
Notable institutional backers of Innoviva, Inc. include Renaissance Technologies, Millennium Management, Systematic Financial Management, L.P., according to Nexqual as of October 29, 2026 at 23:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 5.59% |
| Millennium Management | 3.52% |
| Systematic Financial Management, L.P. | 2.8% |
| Boston Partners | 2.67% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio | 1.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 15.99% |
| Vanguard Group | 10.21% |
| Dimensional Fund Advisors | 6.22% |
| State Street | 4.52% |
| Geode Capital | 2.87% |
Source: Nexqual, October 29, 2026 at 23:44 UTC.
From Innoviva, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Despite the continued use of effective antibiotics, it remains one of the most common sexually transmitted bacterial infections in the world with an estimated 82 million people worldwide infected each year, including over 1 million people each year in the United States.
- During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application ("ANDA") or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all of the data required for approval.
- On February 15, 2022, La Jolla received a paragraph IV notice of certification (the "Notice Letter") from Gland Pharma Limited ("Gland") advising that Gland had submitted an Abbreviated New Drug Application ("ANDA") to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA® in the U.S. prior to the expiration of U.S.
- In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or the FDCA, the Public Health Service Act, or PHSA, and implementing regulations.
Partnerships
- Our distribution and license agreement with Basilea requires that the drug product is manufactured in accordance with the FDA's cGMPs and all other applicable laws and regulations.
- In November 2002, we entered into our LABA Collaboration Agreement with GSK to develop and commercialize once‑daily products for the treatment of chronic obstructive pulmonary disease ("COPD") and asthma.
Legal & Regulatory Risks (Item 1A, quoted)
- The regulatory approval process is expensive, time-consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.
- Any adverse developments to the regulatory status of either RELVAR®/BREO® ELLIPTA® or ANORO® ELLIPTA® in the countries in which they have received regulatory approval, including labeling restrictions, safety findings, or any other limitation to usage, would harm our business and may cause the price of our securities to fall.
- Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.
- We rely on third parties to conduct the clinical trials for our products and product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with applicable regulatory requirements.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 317.33 | ▼ 0.45% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 23:44 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt